Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.70 |
| ▸ | PDE1A | P54750 | 7/20 | 0.70 |
| ▸ | PDE1B | Q01064 | 7/20 | 0.70 |
| ▸ | PDE1C | Q14123 | 7/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.70 |
| ▸ | PDE6A | P16499 | 2/20 | 0.69 |
| ▸ | PDE2A | O00408 | 1/20 | 0.69 |
| ▸ | PDE6D | O43924 | 1/20 | 0.69 |
| ▸ | PDE9A | O76083 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | PDE6G | P18545 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | PDE6B | P35913 | 1/20 | 0.69 |
| ▸ | PDE6C | P51160 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064833 | 1.00 | PDE5A (0.70) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL21995397 | 0.96 | PDE5A (0.67) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL31064888 | 0.96 | PDE5A (0.67) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL22041072 | 0.91 | PDE5A (0.73) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL22041079 | 0.90 | PDE5A (0.71) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL22041438 | 0.90 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL21995694 | 0.88 | PDE5A (0.70) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL28917971 | 0.87 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL21995254 | 0.87 | PDE5A (0.70) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL21995252 | 0.87 | PDE5A (0.70) | PDE5APDE1APDE1BPDE1CPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166157-A | Novel double-acting mode soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2021-07-23 | — | — | CN | claimed |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3887376-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166157-A | Novel double-acting mode soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020109354-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020109354-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE9A, PDE5A, PDE2A | PDE5A 2/4885PDE1A 26/4885PDE1B 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.